Medication info
Rocan Duo Tablets 10/8 mg

Rocan Duo Tablets 10/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Alvogen Korea Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702400 · Approved 2017.05.16 · Insurance code 652606370

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the risk of atherosclerosis and cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil, taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
1. Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. 2. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Alvogen Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the risk of atherosclerosis and cardiovascular disease

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • reduced left ventricular ejection fraction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
View approved original text

This drug is used for patients who need to take both Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is prescribed for patients with essential hypertension and heart failure symptoms, especially in cases of impaired left ventricular function. It is also beneficial for heart failure patients in whom ACE inhibitor treatment is insufficient or poorly tolerated. Rosuvastatin is used for hypercholesterolemia, especially in patients with familial hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise. Additionally, it is effective in delaying the progression of atherosclerosis in hypercholesterolemia patients and reducing the risk of stroke, myocardial infarction, and arterial revascularization. This drug is used for the treatment and risk reduction of hypertension, heart failure, and dyslipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil, taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

1. Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. 2. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Precautions

This drug can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Pregnant women, nursing mothers, and fertile women not using adequate contraception should not take this drug. Patients with liver or kidney function problems, muscle diseases, and certain genetic disorders should not take this drug. Elderly patients, patients with hyperkalemia, and those with impaired liver function should use this drug cautiously, and should consult a doctor immediately if symptoms such as muscle pain or weakness occur. This drug can affect the liver and muscles, so it is important to regularly check liver function tests and muscle enzyme levels before and during treatment. When taken with other antihypertensives, diuretics, anticoagulants, etc., there may be interactions, so consultation with healthcare professionals is necessary. While taking this drug, any sudden dizziness, fatigue, or muscle pain should be reported immediately, and caution is needed when driving or operating machinery. It is not recommended for children as safety and efficacy have not been established. In case of overdose, seek medical attention immediately, and store in a place out of reach of children.

Side effects

headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, positional dizziness, papule, periodontitis, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, interstitial lung disease, sexual dysfunction, gynecomastia, memory decline, forgetfulness, amnesia, memory impairment, confusion, paralysis, anxiety, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbance, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, elevated AST, elevated γ-GTP, liver dysfunction, jaundice, angioedema, increased blood pressure, cerebral infarction, spondyloarthritis with myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, exacerbation of hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, weakness, hunger, cold sweat, hand tremors, decreased concentration, convulsions, altered consciousness, intestinal vascular edema, diarrhea, hepatitis, rash, urticaria, angioedema, myalgia, weakness, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, thrombocytopenia, increased serum creatinine, acute renal failure, oliguria, increased CK, constipation, elevated AST, numbness, sensory disturbance, chest discomfort, abdominal pain, anorexia, abdominal distension, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to keep the storage temperature between 1°C and 30°C at room temperature. This will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.